Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial

HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) for ORPATHYS in combination with TAGRISSO for the treatment of MET-driven EGFR-mutated non-small cell lung cancer (NSCLC). This filing aims to provide a biomarker-directed, all-oral treatment option for patients who have progressed on EGFR-TKI therapy, supported by the Phase III SAFFRON trial, which showed significant improvements in progression-free and overall survival.